Do antiplatelet agents reduce myocardial infarction or death in people with CKD and those treated with dialysis?
In patients with CKD and those on dialysis, antiplatelet agents reduce myocardial infarction but increase major bleeding without a mortality benefit.
Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all-cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain.
Natale et al. (Mon,) studied this question.